Basic Information
| LncRNA/CircRNA Name | PANDAR |
| Synonyms | NA |
| Region | GRCh38_6:36673621-36675126 |
| Ensemble | ENSG00000281450 |
| Refseq | NR_109836 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | retinoblastoma |
| ICD-0-3 | C69.2 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | retinoblastoma tissues, cell lines (ARPE-19, WERI-Rb1 and Y79) |
| Expression Pattern | up-regulated |
| Function Description | PANDAR was increased in RB tissues and cells, and this upregulation was associated with advanced IIRC stage, positive optic nerve invasion, and lower differentiation grade in RB patients. In addition, SP1 could bind directly to the PANDAR promoter region and activate its transcription. PANDAR interference inhibits cell proliferation and induces apoptosisin vitro. Furthermore, PANDAR silencing yielded tumor suppressive effects both in vitro and in vivo. Importantly, PANDAR protects against apoptosis partly by affecting Bcl-2/caspase-3 pathway. |
| Pubmed ID | 29778422 |
| Year | 2018 |
| Title | SP1-induced Upregulation of lncRNA PANDAR Predicts Adverse Phenotypes in Retinoblastoma and Regulates Cell Growth and Apoptosis in Vitro and in Vivo |
External Links
| Links for PANDAR | GenBank HGNC NONCODE |
| Links for retinoblastoma | OMIM COSMIC |